BOLD
Audentes Therapeutics Inc
Halal Rating :
Last Price
$2.48
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Note: Audentes Therapeutics Inc (BOLD) was acquired by Astellas Pharma Inc in January 2020 for $3 billion. The company is no longer publicly traded.
Audentes Therapeutics was a biotechnology company focused on developing and commercializing gene therapy products for patients with serious rare neuromuscular diseases. The company's lead product candidate was AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM).
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Audentes Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.